American Diabetes Association. Diabetes statistics. National Diabetes Fact Sheet. Available at: http://diabetes.org. Accessed October 20, 2005.
2.
Mokdad AH, Ford ES, Bowman A, et al.Diabetes trends in the US: 1990-1998. Diabetes Care. 2000;23:1278-1283.
3.
Mokdad AH, Ford ES, Bowman BA, et al.The continuing increase of diabetes in the US. Diabetes Care. 2001;24:412-412.
4.
Mokdad AH, Bowman BA, Ford ES, et al.The continuing epidemics of obesity and diabetes in the United States. JAMA. 2001;286:1195-2000.
5.
Mokdad AH, Serdula MK, Dietz WH, et al.The spread of the obesity epidemic in the United States, 1991-1998. JAMA. 1999; 282:1519-1522.
6.
UK Prospective Diabetes Study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease. UK Prospective Diabetes Study Group. Diabetes. 1995;44:1249-1258.
7.
Brunzell JD, Robertson RP, Lerner RL, et al.Relationships between fasting plasma glucose levels and insulin secretion during intravenous glucose tolerance tests. J Clin Endocrinol Metab. 1976;42:222-229.
8.
American Diabetes Association. Standards of medical care in diabetes. Diabetes Care.2005;28(suppl 1):S4-S36.
9.
American Diabetes Association. Hypertension management in adults with diabetes. Diabetes Care. 2004;27(suppl 1):S65-S67.
10.
American Diabetes Association. Dyslipidemia management in adults with diabetes. Diabetes Care. 2004;27(suppl 1):S68-S71.
11.
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998;317:703-713.
12.
Gaede P, Vedel P, Larsen N, et al.Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med.2003;348:383-393.
13.
American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists medical guidelines for the management of diabetes mellitus: the AACE system of intensive diabetes self-management—2002 update. Endocr Pract. 2002;8(suppl 1):43-56.
14.
Stratton IM, Adler AI, Neil HA, et al.Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ.2000;321:405-412.
15.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA.2001;285:2486-2497.
16.
Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.
American Diabetes Association. Other diabetes medications. Available at: www.diabetes.org/type-2-diabetes/oral-medications.jsp. Accessed October 26, 2005.
19.
Aviles-Santa L, Sinding J, Raskin P.Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Ann Intern Med.1999;131:182-188.
20.
Bell DS.Beta-cell rejuvenation with thiazolidinediones. Am J Med.2003;115(suppl 8A):20S-23S.
21.
Physicians’ Desk Reference. 59th ed.Montvale, NJ: Thomson PDR; 2005.
22.
Yki-Jarvinen H, Dressler A, Ziemen M.Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care. 2000;23:1130-1136.
23.
Riddle MC.The underuse of insulin therapy in North America. Diabetes Metab Res Rev.2002;18(suppl 3):S42-S49.
24.
Scarlett JA, Gray RS, Griffin J, et al.Insulin treatment reverses the insulin resistance of type II diabetes mellitus. Diabetes Care.1982;5:353-363.
25.
Andrews WJ, Vasquez B, Nagulesparan M, et al.Insulin therapy in obese, non-insulin-dependent diabetes induces improvements in insulin action and secretion that are maintained for two weeks after insulin withdrawal. Diabetes.1984;33:634-642.
26.
Garvey WT, Olefsky JM, Griffin J, et al.The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes.1985;34:222-234.
27.
Schwartz S, Sievers R, Strange P, et al.Insulin 70/30 mix plus metformin versus triple oral therapy in the treatment of type 2 diabetes after failure of two oral drugs: efficacy, safety, and cost analysis. Diabetes Care.2003;26:2238-2243.
28.
American Diabetes Association. Resource guide 2005. Insulin (for type 1/type 2). Available at: http://www.diabetes.org/rg2005/insulin.jsp. Accessed October 24, 2005.
29.
Rosenstock J, Wyne K.Insulin treatment in type 2 diabetes. In: Goldstein BJ, Muller-Wieland D, eds. Textbook of Type 2 Diabetes. London, UK: Martin Dunitz Ltd; 2003;131-154.
30.
Monnier L, Lapinski H, Colette C.Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care.2003;26: 881-885.
31.
Janka HU, Plewe G, Riddle MC, et al.Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care.2005;28:254-259.
32.
Riddle MC, Rosenstock J, Gerich J, et al.The Treat-to-Target Trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care.2003; 26:3080-3086.
33.
Lepore M, Pampanelli S, Fanelli C, et al.Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes.2000;49:2142-2148.
34.
Howey DC, Bowsher RR, Brunelle RL, Woodworth JR.[Lys(B28), Pro(B29)]-human insulin: a rapidly absorbed analogue of human insulin. Diabetes.1994;43:396-402.
35.
von Mach MA, Brinkmann C, Hansen T, et al.Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers. Exp Clin Endocrinol Diabetes.2002;110:416-419.
36.
Dreyer M, Prager R, Robinson A, et al.Efficacy and safety of insulin glulisine (GLU) and insulin lispro (IL), combined with insulin glargine (GLAR) in patients with type 1 diabetes. Poster presented at: 64th Annual Scientific Sessions of the American Diabetes Association; June 4-8, 2004; Orlando, Fla. Abstract 520-P.
37.
Dailey G, Rosenstock J, Moses R, Ways K.Glycemic control with insulin glulisine versus regular human insulin in a basal-bolus regimen in patients with type 2 diabetes. Poster presented at: 64th Annual Scientific Sessions of the American Diabetes Association; June 4-8, 2004; Orlando, Fla. Abstract 514-P.
